Private company
Oryzon Genomics
Oryzon Genomics is a Spanish genomics company based in Barcelona, founded in 2000.1
Oryzon Genomics S.A. ist ein spanisches Unternehmen der Biopharmazie, insbesondere der Epigenetik. Das an der spanischen Börse notierte Unternehmen mit Sitz in Cornellà de Llobregat erforscht medizinische Ansätze zur Behandlung von onkologischen Erkrankungen sowie Störungen des zentralen Nervensystems.2 From the German Wikipedia, CC BY-SA 4.0
Last updated Oct 21, 2026.
Overview
- Industrygenomics1
- HeadquartersBarcelona, Spain1
- Websitewww.oryzon.com
- Legal formSociedad Anonima3
- LEI95980063R15RDF29DK133
- StatusActive3
- LEI statusIssued and current3
- Registered addressCARRERA DE SAN JERÓNIMO 15 2, 28014 Madrid, Spain3
- Registered withRegistrars of Spain, 10002997800763
Timeline
- 2000Founded Founded1
Calendar
Drug trials and FDA: recently
- Oct 30, 2023Phase 2 trial completed Phase 2 trial of vafidemstat in Borderline Personality Disorder: primary completion Oct 30, 2023, results posted May 5, 2026 (ClinicalTrials.gov NCT04932291).4
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar
Links
- Websitewww.oryzon.com1
- WikidataQ30291098
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataOryzon Genomics on Wikidata
- 2
- 3
- 4